IMMU Mendus AB (publ)
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About Mendus (STO: IMMU)
›
Mendus (STO: IMMU) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 18 employees.
The shares were at 3.430 SEK on 19 November 2026, down 41.9% over 52 weeks. Its 52-week range is 3.430 SEK to 8.490 SEK, and it trades at the bottom of that range.
Its market capitalisation is 220.49M SEK.
Mendus reports return on equity of -19.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 37.83M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.